CLINICAL TRIALS PROFILE FOR RETROVIR
✉ Email this page to a colleague
All Clinical Trials for Retrovir
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000662 ↗ | A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease | Completed | Glaxo Wellcome | N/A | 1969-12-31 | To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT. |
| NCT00000662 ↗ | A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT. |
| NCT00000716 ↗ | A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 1969-12-31 | To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24 weeks to children between 3 months and 12 years of age. The effectiveness of AZT in treating HIV infection in infants and children will also be evaluated. HIV infection in children is most often associated with symptomatic disease and poor prognosis. Treatment with antiviral therapy may be effective in altering the course of the disease and decreasing mortality in these children. AZT has been shown to be effective in certain adult patients with symptomatic HIV infection. It is therefore likely that infected children may also benefit from this treatment. |
| NCT00002020 ↗ | Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC | Completed | Glaxo Wellcome | N/A | 1969-12-31 | To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours. |
| NCT00002028 ↗ | A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir) | Completed | Bristol-Myers Squibb | N/A | 1969-12-31 | The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program due to protocol exclusion or geographic location. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Retrovir
Condition Name
Clinical Trial Locations for Retrovir
Trials by Country
Clinical Trial Progress for Retrovir
Clinical Trial Phase
Clinical Trial Sponsors for Retrovir
Sponsor Name
| Sponsor Name for Retrovir | |
| Sponsor | Trials |
| Glaxo Wellcome | 15 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 11 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 6 |
| [disabled in preview] | 9 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
